![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
Previous Article | Next Article 
Infection and Immunity, April 2002, p. 2151-2158, Vol. 70, No. 4
0019-9567/02/$04.00+0 DOI: 10.1128/IAI.70.4.2151-2158.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.
Department of Veterinary Pathology, College of Veterinary Medicine, Iowa State University, Ames, Iowa 50011,1 Department of Pathobiology, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 191042
Received 13 September 2001/ Returned for modification 1 November 2001/ Accepted 21 December 2001
 |
ABSTRACT |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
|
INTRODUCTION |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Recent work has shown that the in vivo T-cell response towards Leishmania amazonensis is different from that described for other Leishmania species. The chronic lesions characteristic of L. amazonensis infection in C57BL/6 and C57BL/10 mice are independent of expression of IL-4 and a corresponding Th2 response (2, 23). In addition, L. amazonensis infection in C3H mice results in low levels of production of IL-12 and gamma interferon (IFN-
) by antigen-specific CD4+ T cells (23). However, lesion development and parasite burden have been shown to be exacerbated in the presence of CD4+ T cells, demonstrating that T cells are activated during L. amazonensis infection and that they contribute significantly to the immunopathology of the chronic disease (44). We have shown that chronic infection by L. amazonensis in C3H and C57BL/6 mice is persistent even after administration of exogenous IL-12 (23). The inability of IL-12 to drive an effective cell-mediated immune response during L. amazonensis infection suggests that the parasite can evoke a potent immunomodulatory mechanism to evade widespread parasite killing and promote a chronic infection. The importance of understanding the factors involved in maintenance of this chronic disease is highlighted by the fact that chronic cutaneous leishmaniasis in humans is often correlated with a poor T-cell-mediated immune response (43) or a mixed T-cell response (35).
IL-10 has been shown to be a potent immunomodulatory molecule (30). This cytokine has been shown to play a role in limiting IFN- production in T cells via downregulation of IL-12 production in both macrophages and dendritic cells and in downregulating antigen-presenting cell function by decreasing the expression of major histocompatibility complex class II and regulating the responsiveness and/or expression of costimulatory molecules in the antigen-presenting cell population (10, 13, 14-16, 26, 29, 36). In addition, IL-10 has been associated with decreased immune responses to cutaneous leishmaniasis in people (6, 40), and inhibition of IL-10 during the recall response increases IFN- levels (40). However, anti-IL-10 treatment did not alter the course of infection in L. major-susceptible BALB/c mice or L. major-resistant C57BL/6 mice (8). Recent reports have suggested that the primary role of IL-10 during Leishmania infection may be to limit macrophage activation since FcR-mediated uptake of immunoglobulin-opsonized parasites by macrophages leads to IL-10-dependent inhibition of parasite killing (24). These studies also demonstrated that IL-10-deficient BALB/c mice infected with tissue-derived L. major amastigotes had significantly smaller lesions and fewer parasites associated with the lesions than wild-type (WT) control mice (24). In support of these data, a recent study demonstrated that mice deficient in either immunoglobulin production or FcR expression were resistant to L. amazonensis infection, although the role of IL-10 in this infectious disease model is unknown (25).
Since C57BL/6 mice infected with L. amazonensis develop chronic lesions with a persistent parasite burden independent of a Th2 response, we tested the hypothesis that IL-10 is responsible for limiting the host immune response during such an infection. At 4 weeks postinfection, the tissue parasite load was decreased and there was an enhanced Th1 response in the absence of IL-10. However, at a more chronic stage of infection, parasites persisted within the lesions and there was no increase in the Th1 response in the draining lymph nodes (LN). In addition, lower numbers of IFN--producing cells in the draining LN and lower levels of Leishmania-specific immunoglobulin G2a (IgG2a) antibody in the IL-10-deficient mice suggested that in vivo IFN- levels were not enhanced in the IL-10-deficient mice compared to those of WT mice. In contrast, the positive delayed-type hypersensitivity (DTH) response at 15 weeks postinfection demonstrated that potential Th1 immune effector cells were present in vivo. These results indicate that IL-10 does limit parasiticidal activity in the host but does not play a major role in determining the phenotype of the Th response during L. amazonensis infection.
|
MATERIALS AND METHODS |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Mice. Female C57BL/6 and B6.129P2-Il10tm1Cgn mice were purchased from Jackson Laboratory (Bar Harbor, Maine). The mice were maintained in a specific-pathogen-free facility. The Committee on Animal Care at Iowa State University approved all protocols involving animals. Each mouse was inoculated with 5 x 106 stationary-phase promastigotes in 50 µl of PBS in a hind footpad. Lesion size was monitored with a dial micrometer (L. S. Starrett Co., Athol, Mass.), and the results were expressed as the difference between the footpad thickness for the uninfected foot and the footpad thickness for the infected foot.
DTH response. At 15 weeks postinfection, the uninfected right hind foot of each mouse was measured, and 20-µg portions of FT-ag in 50 µl of PBS were injected into one-half of the infected mice; each of the other mice received an injection consisting of 50 µl of PBS in the subcutaneous tissue of the uninfected hind foot. At 24 h after antigen injection the right hind foot of each mouse was measured again. No increase in footpad thickness was detected at this time in the PBS-challenged mice (data not shown).
Recall response and ELISPOT analyses.
LN cells draining the infected feet were obtained 4 and 15 weeks postinfection as indicated below. The cells were disassociated with a Tenbrock tissue homogenizer and were resuspended in complete tissue culture medium (Dulbecco's minimal essential medium containing 4.5 mg of glucose/ml, 2 mM L-glutamine, 100 U of penicillin 6-potassium/ml, 100 mg of streptomycin/ml, 25 mM HEPES, and 50 µM 2-mercaptoethanol) at a density of 5 x 106 cells per ml in a final volume of 200 µl in U-bottom or flat-bottom 96-well plates. The cells were incubated in medium only (unstimulated), or they were stimulated with 50 µg of FT-ag per ml. Supernatants were harvested after 72 h, and IFN- and IL-4 levels were determined by enzyme-linked immunosorbent assays (ELISA); the sensitivity of both assays was 
39 pg/ml. The numbers of IL-12p40- and IFN--producing cells were determined ex vivo by using enzyme-linked immunospot (ELISPOT) assays with 4- and 12-h incubations, respectively, as described previously (41). The ELISA and IFN- and IL-12 ELISPOT assays were performed with commercially available antibodies (BD Pharmingen, San Diego, Calif.).
IgG2a antibody titers. Leishmania-specific antibody contents were determined by using an ELISA based on a previously described assay (46). Briefly, polystyrene microtiter plates (Becton Dickinson, Franklin Lakes, N.J.) were coated with 1.0 µg of L. major FT-ag per ml or 1.0 µg of L. amazonensis FT-ag per ml in PBS (pH 9.4) overnight at 4°C. The plates were washed as described previously and blocked with 5% nonfat dry milk (Carnation) in PBS-0.05% Tween 20 for 2 h at 37°C. Serum samples were then serially diluted with 0.05% Tween 20 in PBS starting at a dilution of 1:100. The samples were incubated overnight at 4°C. The plates were washed in PBS-0.05% Tween 20 five times, and bound antibodies were detected with goat anti-mouse IgG2a directly conjugated to horseradish peroxidase (Southern Biotechnology Associates, Birmingham, Ala.) and diluted 1:5,000 in PBS containing 25% normal goat serum (pH 9.4). After 2 h of incubation at 37°C, the plates were washed with PBS-0.05% Tween 20, and the 2,2'-azinobis(3-ethylbenzthiazolinesulfonic acid) (ABTS) peroxidase substrate (Kirkegaard and Perry Laboratories, Gaithersburg, Md.) was then added. The plates were read at A405 with a microplate reader (Molecular Devices, Sunnyvale, Calif.). The antibody titer was expressed as the optical density at 405 nm of the 1:300 dilution. All sera from uninfected animals were negative, as determined by optical densities at 405 nm of 1:300 dilutions (data not shown).
Immunohistochemistry. At different times after infection, tissue from each mouse was fixed in 10% buffered formalin and routinely processed for paraffin-imbedded sectioning, and then 8-µm-thick sections were cut, applied to poly-L-lysine-coated slides, and stained with hematoxylin and eosin. Additional unstained sections were used for immunohistochemical detection of inducible nitric oxide synthase (iNOS) expression. Briefly, slides were incubated in a 1:10,000 dilution of a polyclonal rabbit IgG anti-mouse iNOS antibody (06-573; Upstate Biotechnology Incorporated, Lake Placid, N.Y.) in primary dilution buffer (Optimax; BioGenex, San Ramon, Calif.). Control sections were incubated with polyclonal rabbit IgG (12-370; Upstate Biotechnology). The primary antibody was detected by using adsorbed affinity-purified biotinylated goat anti-rabbit antibody (076-15-061; Kirkegaard and Perry) at a dilution of 1:200 in Optimax primary diluent. Super-sensitive-streptavidin-conjugated peroxidase was used for secondary antibody detection (BioGenex), and the signal was generated by using Nova Red (Vector Laboratories, Burlingame, Calif.). Tissue sections were then counterstained with Shandon's hematoxylin. Control sections were negative, as were footpad sections stained for iNOS from uninfected animals (data not shown).
Statistical procedures.
Statistical significance was determined by analysis of variance by using StatView (SAS Institute Inc.). Differences between means were considered significant if P was 
0.05. Results are presented below as means ± standard errors, unless indicated otherwise.
|
RESULTS |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
|
|
|
production.
An analysis of the numbers of IFN--producing cells in the draining LN at 4 weeks postinfection demonstrated that the numbers of these cells were greater than the numbers in uninfected animals in both the IL-10-deficient mice and the WT mice. In contrast to the numbers of IL-12-producing cells, there were fewer cells producing IFN- in the IL-10-deficient mice than in the WT mice, although the background levels in uninfected animals were not statistically different (Fig. 3B). Therefore, the postinfection increase in the numbers of IFN--producing cells compared to the levels in uninfected animals was greater for the WT mice (8.11-fold increase) than for the IL-10-deficient mice (6.88-fold increase).
Despite the lower numbers of IFN--producing cells detected ex vivo in the draining LN, the antigen-specific recall response at 4 weeks postinfection demonstrated that LN cells from infected IL-10-deficient mice did have the potential to produce more IFN- than LN cells from infected WT mice could produce. However, at 15 weeks postinfection, when there was still a persistent parasite load in the IL-10-deficient mice, these mice did not have increased IFN- in the recall response compared to the IFN- in the recall response in infected WT mice. In addition, the levels of IFN- produced in both groups of mice were less than the levels detected with the recall response at 4 weeks postinfection (Fig. 4). At 4 weeks postinfection IL-4 production was low in both the IL-10-deficient mice and the WT mice (mean production, 74 ± 80 and 73 ± 115.6 pg/ml, respectively). At 15 weeks postinfection there was 39.2 ± 97 pg of IL-4 per ml in the recall response of the IL-10-deficient mice and no IL-4 was detected in the WT mice.
|
production during the immune response. Figure 5 shows that at 15 weeks after L. amazonensis infection there was a significant decrease in the level of Leishmania-specific IgG2a isotype antibodies in the IL-10-deficient mice compared to the level in the WT control mice. These results are in agreement with the ELISPOT assay results which indicated that lower levels of IFN- were expressed in vivo in the IL-10-deficient mice.
|
|
|
DISCUSSION |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
In our analysis of the IL-10-deficient mice after L. amazonensis infection, we detected an increase in the amount of IFN- in the recall response of the draining LN at 4 weeks after infection (Fig. 4). Although we did not determine the source of IFN-, the increase did correlate with a small but significant increase in the number of IL-12-producing cells in the draining LN and an enhanced DTH response. These results are consistent with an increase in a T-cell-mediated response and suggest that there is some biological significance to the increase in IL-12. The modest increase in the Th1 response after L. amazonensis infection is in contrast to the immune response of IL-10-deficient mice infected with T. gondii or T. cruzi. Systemic infections with these protozoans caused an immune hyperactivity that resulted in a lethal immune response mediated by IFN- from CD4+ T cells (17, 22, 31). In addition, in our experiments, the ratio of IFN--producing cells in the LN of infected mice to IFN--producing cells in the LN of uninfected mice was not greater for the IL-10-deficient mice than for the WT mice (Fig. 3B). In fact, the decrease in the number of IFN--producing cells in the L. amazonensis-infected IL-10-deficient mice suggests that in the absence of IL-10, significant immunomodulatory mechanisms that limit IFN- production in vivo are upregulated. This conclusion is supported by the fact that the titers of IFN--dependent Leishmania-specific IgG2a isotype antibodies were lower in the IL-10-deficient mice than in the WT mice (Fig. 5). Together, the data clearly indicate that any enhancement of the Th1 response due to the absence of host IL-10 is insufficient for an effective cell-mediated immune response to L. amazonensis and resolution of the infection.
There have been several studies demonstrating the association of IL-10 production with leishmanial infection in human and experimental murine infections. In these studies neutralization of IL-10 during in vitro analysis indicated that IL-10 plays a role in limiting IFN- production from CD4+ T cells and NK cells during Leishmania infection (40, 41). However, recent studies have demonstrated that during cutaneous leishmaniasis, IL-10 promotes parasite survival by influencing macrophage activation and that the role of IL-10 in determining the phenotype of the T-cell response is less important (18, 19, 24). In our studies, the observation that there is a low level of in vivo IFN- production but a high level of iNOS expression (Fig. 2D) with a decreased parasite load is consistent with the hypothesis that IL-10 plays a primary role in limiting macrophage activation during cutaneous leishmaniasis. The iNOS expression detected at 15 weeks postinfection (data not shown) suggests that there is persistent macrophage activation during later stages of the disease. These results are consistent with previous studies demonstrating the importance of NO in limiting parasite numbers in mice chronically infected with L. major (47). However, the persistence of L. amazonensis parasites in the IL-10-deficient mice indicates that the presence of these parasites during chronic infection is only partially dependent on expression of host IL-10.
After 15 weeks, localized footpad infection by L. amazonensis becomes relatively quiescent, and there is no increase in IL-12-producing cells in the draining LN, even in the presence of readily detectable parasites (data not shown). In addition, there is no detectable increase in the antigen-specific Th1 response in the draining LN of IL-10-deficient mice at this time (Fig. 4). Given the absence of a sustained increase in these parameters for the Th1 type of immunity in the draining LN, these results suggest that regulation of the Th1 response is independent of IL-10. These results are similar to those described for infection of IL-10-deficient mice with S. mansoni, which resulted in an increase in Th1 cytokines and a mixed Th1/Th2 immune phenotype during the acute immune response. As the disease progressed to a chronic stage, there was downregulation of Th1-associated cytokines. This regulation of the enhanced Th1 response was subsequently shown to be dependent on endogenous IL-4 (20, 49). Previous work with L. amazonensis has demonstrated that IL-4 does not play a role in limiting the immune response during this infection (2, 23). In agreement with the previous studies, very little IL-4 was detected in the recall responses of L. amazonensis-infected mice, whether they were IL-10-deficient mice or control mice. Therefore, we believe that downregulation of the Th1 response in L. amazonensis-infected IL-10-deficient mice is independent of IL-4.
The enhanced DTH response of L. amazonensis-infected IL-10-deficient mice does demonstrate that Th1 effector cells are present in vivo (Fig. 6). Previous studies have shown that IL-10 can inhibit the DTH response, at least in part, by limiting vascular permeability and swelling during the DTH response (28). Increases in these parameters of footpad swelling in IL-10-deficient mice during infection could account for the finding that the lesion size was equivalent to that in WT mice, even though the parasite load in the tissue was 1 to 2 logs lower in the IL-10-deficient mice. The dichotomy between the enhanced DTH response and the low IFN- levels detected in the recall response of the draining LN could be reconciled if the antigen interaction with the antigen-presenting cell-T-cell stimulation pathway in vivo was limited. This scenario could suggest that there are more antigen-specific memory T cells in the peripheral tissue and fewer antigen-specific Th1 effector, IFN--producing cells in the draining LN. An increase in the peripheral activated memory cells has been described previously for IL-10-deficient mice, and it has recently been shown that few Th1 effector cells occur in secondary lymphoid organs in mice after an antigen challenge (3, 38). Regulation of antigen presentation in vivo would be consistent with in vitro data for the same organism that demonstrated that this parasite has several methods that prevent antigen stimulation of T cells (1, 4, 12, 34). Alternatively, increased iNOS expression is a possible mechanism of Th1 suppression through increased nitric oxide levels. This could account for local regulation of the immune response at the draining LN and is consistent with the role of nitric oxide in limiting T-cell responses during other intracellular protozoan infections, including infections of IL-10-deficient mice with Toxoplasma and infections of C57BL/6 mice with L. major (21, 31). Work is under way to determine what IL-10-independent mechanisms regulate the IL-12-producing cells and the Th1 cells that are detected in the recall response at 4 weeks postinfection and in the DTH response at 15 weeks postinfection.
In conclusion, the data presented here demonstrate that in the mouse model of cutaneous leishmaniasis, susceptibility to L. amazonensis is dependent not only on expression of IL-10. L. amazonensis parasites persist in IL-10-deficient mice, even in the presence of an enhanced Th1 response during the early stages of infection and in the presence of antigen-specific cells primed for Th1 effector function during the chronic phase. These persistent parasites are associated with chronic nonhealing lesions. Our results are consistent with a model proposing that IL-10 expression during Leishmania infection is important more for determining the level of macrophage activation and subsequent leishmanicidal activity than for influencing the T-cell response. Our results also demonstrate that L. amazonensis can evoke IL-10-independent mechanisms to limit in vivo IFN- production. Understanding these mechanisms at the systemic and cellular levels is necessary for us to propose adequate immunomodulatory strategies for preventive or curative procedures.
|
ACKNOWLEDGMENTS |
|---|
This work was supported by National Institutes of Health grants AI48357, AI35914, and AI42334. Additional funds were provided by the Office of Biotechnology and the College of Veterinary Medicine at Iowa State University.
|
FOOTNOTES |
|---|
|
REFERENCES |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
| 1. | Aebischer, T., D. Harbecke, and T. Ilg. 1999. Proteophosphoglycan, a major secreted product of intracellular Leishmania mexicana amastigotes, is a poor B-cell antigen and does not elicit a specific conventional CD4+ T-cell response. Infect. Immun. 67:5379-5385. |
| 2. | Afonso, L. C., and P. Scott. 1993. Immune responses associated with susceptibility of C57BL/10 mice to Leishmania amazonensis. Infect. Immun. 61:2952-2959. |
| 3. | Annacker, O., R. Pimenta-Araujo, O. Burlen-Defranoux, T. C. Barbosa, A. Cumano, and A. Bandeira. 2001. CD25+ CD4+ T cells regulate the expansion of peripheral CD4 T cells through the production of IL-10. J. Immunol. 166:3008-3018. |
| 4. | Antoine, J. C., T. Lang, E. Prina, N. Courret, and R. Hellio. 1999. H-2M molecules, like MHC class II molecules, are targeted to parasitophorous vacuoles of Leishmania-infected macrophages and internalized by amastigotes of L. amazonensis and L. mexicana. J. Cell Sci. 112:2559-2570.[Abstract] |
| 5. | Barral, A., E. A. Petersen, D. L. Sacks, and F. A. Neva. 1983. Late metastatic leishmaniasis in the mouse. A model for mucocutaneous disease. Am. J. Trop. Med. Hyg. 32:277-285. |
| 6. | Bomfim, G., C. Nascimento, J. Costa, E. M. Carvalho, M. Barral-Netto, and A. Barral. 1996. Variation of cytokine patterns related to therapeutic response in diffuse cutaneous leishmaniasis. Exp. Parasitol. 84:188-194.[CrossRef][Medline] |
| 7. | Calabrese, K. D. S., and S. C. da Costa. 1992. Enhancement of Leishmania amazonensis infection in BCG non-responder mice by BCG-antigen specific vaccine. Mem. Inst. Oswaldo Cruz 1:49-56. |
| 8. | Chatelain, R., S. Mauze, and R. L. Coffman. 1999. Experimental Leishmania major infection in mice: role of IL-10. Parasite Immunol. 21:211-218.[CrossRef][Medline] |
| 9. | Childs, G. E., L. K. Lightner, L. McKinney, M. G. Groves, E. E. Price, and L. D. Hendricks. 1984. Inbred mice as model hosts for cutaneous leishmaniasis. I. Resistance and susceptibility to infection with Leishmania braziliensis. L. mexicana, and L. aethiopica. Ann. Trop. Med. Parasitol. 78:25-34.[Medline] |
| 10. | D'Andrea, A., M. Aste-Amezaga, N. M. Valiante, X. Ma, M. Kubin, and G. Trinchieri. 1993. Interleukin 10 (IL-10) inhibits human lymphocyte interferon gamma-production by suppressing natural killer cell stimulatory factor/IL-12 synthesis in accessory cells. J. Exp. Med. 178:1041-1048. |
| 11. | DeKrey, G. K., H. C. Lima, and R. G. Titus. 1998. Analysis of the immune responses of mice to infection with Leishmania braziliensis. Infect. Immun. 66:827-829. |
| 12. | De Souza Leao, S., T. Lang, E. Prina, R. Hellio, and J. C. Antoine. 1995. Intracellular Leishmania amazonensis amastigotes internalize and degrade MHC class II molecules of their host cells. J. Cell Sci. 108:3219-3231.[Abstract] |
| 13. | de Waal Malefyt, R., J. Haanen, H. Spits, M. G. Roncarolo, A. te Velde, C. Figdor, K. Johnson, R. Kastelein, H. Yssel, and J. E. de Vries. 1991. Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J. Exp. Med. 174:915-924. |
| 14. | Ding, L., P. S. Linsley, L. Y. Huang, R. N. Germain, and E. M. Shevach. 1993. IL-10 inhibits macrophage costimulatory activity by selectively inhibiting the up-regulation of B7 expression. J. Immunol. 151:1224-1234.[Abstract] |
| 15. | Fiorentino, D. F., A. Zlotnik, T. R. Mosmann, M. Howard, and A. O'Garra. 1991. IL-10 inhibits cytokine production by activated macrophages. J. Immunol. 147:3815-3822.[Abstract] |
| 16. | Fiorentino, D. F., A. Zlotnik, P. Vieira, T. R. Mosmann, M. Howard, K. W. Moore, and A. O'Garra. 1991. IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. J. Immunol. 146:3444-3451.[Abstract] |
| 17. | Gazzinelli, R. T., M. Wysocka, S. Hieny, T. Scharton-Kersten, A. Cheever, R. Kuhn, W. Muller, G. Trinchieri, and A. Sher. 1996. In the absence of endogenous IL-10, mice acutely infected with Toxoplasma gondii succumb to a lethal immune response dependent on CD4+ T cells and accompanied by overproduction of IL-12, IFN-gamma and TNF-alpha. J. Immunol. 157:798-805.[Abstract] |
| 18. | Groux, H., F. Cottrez, M. Rouleau, S. Mauze, S. Antonenko, S. Hurst, T. McNeil, M. Bigler, M. G. Roncarolo, and R. L. Coffman. 1999. A transgenic model to analyze the immunoregulatory role of IL-10 secreted by antigen-presenting cells. J. Immunol. 162:1723-1729. |
| 19. | Hagenbaugh, A., S. Sharma, S. M. Dubinett, S. H. Wei, R. Aranda, H. Cheroutre, D. J. Fowell, S. Binder, B. Tsao, R. M. Locksley, K. W. Moore, and M. Kronenberg. 1997. Altered immune responses in interleukin 10 transgenic mice. J. Exp. Med. 185:2101-2110. |
| 20. | Hoffmann, K. F., A. W. Cheever, and T. A. Wynn. 2000. IL-10 and the dangers of immune polarization: excessive type 1 and type 2 cytokine responses induce distinct forms of lethal immunopathology in murine schistosomiasis. J. Immunol. 164:6406-6416. |
| 21. | Huang, F. P., W. Niedbala, X. Q. Wei, D. Xu, G. J. Feng, J. H. Robinson, C. Lam, and F. Y. Liew. 1998. Nitric oxide regulates Th1 cell development through the inhibition of IL-12 synthesis by macrophages. Eur. J. Immunol. 28:4062-4070.[CrossRef][Medline] |
| 22. | Hunter, C. A., L. A. Ellis-Neyes, T. Slifer, S. Kanaly, G. Grunig, M. Fort, D. Rennick, and F. G. Araujo. 1997. IL-10 is required to prevent immune hyperactivity during infection with Trypanosoma cruzi. J. Immunol. 158:3311-3316.[Abstract] |
| 23. | Jones, D. E., L. U. Buxbaum, and P. Scott. 2000. IL-4-independent inhibition of IL-12 responsiveness during Leishmania amazonensis infection. J. Immunol. 165:364-372. |
| 24. | Kane, M. M., and D. M. Mosser. 2001. The role of IL-10 in promoting disease progression in leishmaniasis. J. Immunol. 166:1141-1147. |
| 25. | Kima, P. E., S. L. Constant, L. Hannum, M. Colmenares, K. S. Lee, A. M. Haberman, M. J. Shlomchik, and D. McMahon-Pratt. 2000. Internalization of Leishmania mexicana complex amastigotes via the Fc receptor is required to sustain infection in murine cutaneous leishmaniasis. J. Exp. Med. 191:1063-1068. |
| 26. | Koch, F., U. Stanzl, P. Jennewein, K. Janke, C. Heufler, E. Kampgen, N. Romani, and G. Schuler. 1996. High level IL-12 production by murine dendritic cells: upregulation via MHC class II and CD40 molecules and downregulation by IL-4 and IL-10. J. Exp. Med. 184:741-746. |
| 27. | Kopf, M., F. Brombacher, G. Kohler, G. Kienzle, K. H. Widmann, K. Lefrang, C. Humborg, B. Ledermann, and W. Solbach. 1996. IL-4-deficient Balb/c mice resist infection with Leishmania major. J. Exp. Med. 184:1127-1136. |
| 28. | Li, L., J. F. Elliott, and T. R. Mosmann. 1994. IL-10 inhibits cytokine production, vascular leakage, and swelling during T helper 1 cell-induced delayed-type hypersensitivity. J. Immunol. 153:3967-3978.[Abstract] |
| 29. | Macatonia, S. E., T. M. Doherty, S. C. Knight, and A. O'Garra. 1993. Differential effect of IL-10 on dendritic cell-induced T cell proliferation and IFN-gamma production. J. Immunol. 150:3755-3765.[Abstract] |
| 30. | Moore, K. W., A. O'Garra, R. de Waal Malefyt, P. Vieira, and T. R. Mosmann. 1993. Interleukin-10. Annu. Rev. Immunol. 11:165-190.[CrossRef][Medline] |
| 31. | Neyer, L. E., G. Grunig, M. Fort, J. S. Remington, D. Rennick, and C. A. Hunter. 1997. Role of interleukin-10 in regulation of T-cell-dependent and T-cell-independent mechanisms of resistance to Toxoplasma gondii. Infect. Immun. 65:1675-1682.[Abstract] |
| 32. | Noben-Trauth, N., P. Kropf, and I. Muller. 1996. Susceptibility to Leishmania major infection in interleukin-4-deficient mice. Science 271:987-990.[Abstract] |
| 33. | Noben-Trauth, N., W. E. Paul, and D. L. Sacks. 1999. IL-4- and IL-4 receptor-deficient BALB/c mice reveal differences in susceptibility to Leishmania major parasite substrains. J. Immunol. 162:6132-6140. |
| 34. | Peters, C., M. Kawakami, M. Kaul, T. Ilg, P. Overath, and T. Aebischer. 1997. Secreted proteophosphoglycan of Leishmania mexicana amastigotes activates complement by triggering the mannan binding lectin pathway. Eur. J. Immunol. 27:2666-2672.[Medline] |
| 35. | Pirmez, C., M. Yamamura, K. Uyemura, M. Paes-Oliveira, F. Conceicao-Silva, and R. L. Modlin. 1993. Cytokine patterns in the pathogenesis of human leishmaniasis. J. Clin. Investig. 91:1390-1395. |
| 36. | Poe, J. C., D. H. Wagner, R. W. Miller, R. D. Stout, and J. Suttles. 1997. IL-4 and IL-10 modulation of CD40-mediated signaling of monocyte IL-1beta synthesis and rescue from apoptosis. J. Immunol. 159:846-852.[Abstract] |
| 37. | Reiner, S. L., and R. A. Seder. 1995. T helper cell differentiation in immune response. Curr. Opin. Immunol. 7:360-366.[CrossRef][Medline] |
| 38. | Reinhardt, R. L., A. Khoruts, R. Merica, T. Zell, and M. K. Jenkins. 2001. Visualizing the generation of memory CD4 T cells in the whole body. Nature 410:101-105.[CrossRef][Medline] |
| 39. | Roberts, M., J. Alexander, and J. M. Blackwell. 1990. Genetic analysis of Leishmania mexicana infection in mice: single gene (Scl-2) controlled predisposition to cutaneous lesion development. J. Immunogen. 17:89-100. |
| 40. | Rocha, P. N., R. P. Almeida, O. Bacellar, A. R. de Jesus, D. C. Filho, A. C. Filho, A. Barral, R. L. Coffman, and E. M. Carvalho. 1999. Down-regulation of Th1 type of response in early human American cutaneous leishmaniasis. J. Infect. Dis. 180:1731-1734.[CrossRef][Medline] |
| 41. | Scharton-Kersten, T., L. C. Afonso, M. Wysocka, G. Trinchieri, and P. Scott. 1995. IL-12 is required for natural killer cell activation and subsequent T helper 1 cell development in experimental leishmaniasis. J. Immunol. 154:5320-5330.[Abstract] |
| 42. | Sher, A., and R. L. Coffman. 1992. Regulation of immunity to parasites by T cells and T cell-derived cytokines. Annu. Rev. Immunol. 10:385-409.[CrossRef][Medline] |
| 43. | Silveira, F. T., R. Lainson, J. J. Shaw, A. A. De Souza, E. A. Ishikawa, and R. R. Braga. 1991. Cutaneous leishmaniasis due to Leishmania (Leishmania) amazonensis in Amazonian Brazil, and the significance of a negative Montenegro skin-test in human infections. Trans. R. Soc. Trop. Med. Hyg. 85:735-738.[CrossRef][Medline] |
| 44. | Soong, L., C. H. Chang, J. Sun, B. J. Longley, Jr., N. H. Ruddle, R. A. Flavell, and D. McMahon-Pratt. 1997. Role of CD4+ T cells in pathogenesis associated with Leishmania amazonensis infection. J. Immunol. 158:5374-5383.[Abstract] |
| 45. | Soong, L., J. C. Xu, I. S. Grewal, P. Kima, J. Sun, B. J. Longley, Jr., N. H. Ruddle, D. McMahon-Pratt, and R. A. Flavell. 1996. Disruption of CD40-CD40 ligand interactions results in an enhanced susceptibility to Leishmania amazonensis infection. Immunity 4:263-273.[CrossRef][Medline] |
| 46. | Stamm, L. M., A. Raisanen-Sokolowski, M. Okano, M. E. Russell, J. R. David, and A. R. Satoskar. 1998. Mice with STAT6-targeted gene disruption develop a Th1 response and control cutaneous leishmaniasis. J. Immunol. 161:6180-6188. |
| 47. | Stenger, S., N. Donhauser, H. Thuring, M. Rollinghoff, and C. Bogdan. 1996. Reactivation of latent leishmaniasis by inhibition of inducible nitric oxide synthase. J. Exp. Med. 183:1501-1514. |
| 48. | Suzuki, Y., A. Sher, G. Yap, D. Park, L. E. Neyer, O. Liesenfeld, M. Fort, H. Kang, and E. Gufwoli. 2000. IL-10 is required for prevention of necrosis in the small intestine and mortality in both genetically resistant BALB/c and susceptible C57BL/6 mice following peroral infection with Toxoplasma gondii. J. Immunol. 164:5375-5382. |
| 49. | Wynn, T. A., A. W. Cheever, M. E. Williams, S. Hieny, P. Caspar, R. Kuhn, W. Muller, and A. Sher. 1998. IL-10 regulates liver pathology in acute murine Schistosomiasis mansoni but is not required for immune down-modulation of chronic disease. J. Immunol. 160:4473-4480. |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| J. Bacteriol. | J. Virol. | Eukaryot. Cell |
|---|
| Microbiol. Mol. Biol. Rev. | Clin. Vaccine Immunol. | All ASM Journals |
|---|
) and IL-10-deficient mice (
). (B) Numbers of parasites in the infected feet at 4 and 15 weeks postinfection (see Materials and Methods). The stippled bars and the solid bars represent data obtained with WT and IL-10-deficient mice, respectively. The values are means ± standard errors based on three experiments performed with three to five mice per group. P was 0.005 and <0.001 for the 4- and 15-week postinfection values, respectively.
